The Pill That Could Double Survival — If Pancreatic Cancer Patients Can Get It

Pancreatic cancer kills more than 52,000 Americans each year. The five-year survival rate sits at 13% — better than the 4.6% recorded in 2000, but still among the lowest of any major malignancy [1]. For the roughly 51% of patients diagnosed after their cancer has already spread to distant organs, the outlook is far worse [2].

Against that backdrop, clinical trial data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting landed with unusual force. Daraxonrasib, a once-daily oral pill developed by Revolution Medicines, reduced the risk of death by 60% compared to standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), delivering a median overall survival of 13.2 months versus 6.7 months [3][4].

The results, published simultaneously in the New England Journal of Medicine, were described by oncologists as a watershed moment for a disease that has resisted meaningful therapeutic progress for decades [5]. But for the estimated 67,530 Americans who will be diagnosed with pancreatic cancer in 2026, the question is not whether the drug works. The question is whether they can get it [1].

Source: Revolution Medicines / NEJM

Data as of Jun 1, 2026CSV

A Drug Decades in the Making

More than 90% of pancreatic cancers harbor mutations in the KRAS oncogene — a protein so central to tumor growth, and so difficult to target pharmacologically, that it was labeled "undruggable" for nearly 40 years [6][7]. The first successful KRAS inhibitors, sotorasib (Lumakras) and adagrasib (Krazati), won FDA approval in 2021 and 2022 respectively, but only for non-small cell lung cancer patients with a specific KRAS G12C mutation — a variant found in just 1–2% of pancreatic tumors [8].

Daraxonrasib represents a different approach. Rather than targeting a single mutation, it is a RAS(ON) multi-selective inhibitor that blocks the active, GTP-bound form of RAS proteins across the G12X family of mutations, which encompasses the vast majority of KRAS-mutant pancreatic cancers [9]. In preclinical and early clinical studies, daraxonrasib disrupted downstream signaling through both the RAF–MEK–ERK and PI3K–AKT pathways [10].

The Phase 3 RASolute 302 trial enrolled 501 patients across the globe. In the core population — patients with KRAS G12X mutations — median overall survival was 13.2 months on daraxonrasib versus 6.6 months on chemotherapy (hazard ratio 0.40; p<0.0001). The drug was generally well tolerated, with no new safety signals [3][4]. An expanded cohort including G13 and Q61 mutations showed broadly consistent results, though sample sizes for those subgroups were smaller [4].

Source: American Cancer Society / SEER

Data as of Jan 1, 2025CSV

The Expanded Access Bottleneck

Daraxonrasib is not yet FDA-approved. Revolution Medicines has stated its intention to file a New Drug Application under the Commissioner's National Priority Voucher pilot program, but no specific submission date has been announced [11]. In the interim, the only legal pathway for patients to receive the drug is through an expanded access treatment protocol (EAP), which the FDA authorized on April 30, 2026 — just 48 hours after receiving Revolution Medicines' request [12][13].

Under the EAP, daraxonrasib is supplied free of charge by Revolution Medicines. But the program has significant constraints. Only a licensed treating physician can submit an access request, directed to medinfo@revmed.com [14]. Patients and caregivers cannot apply directly. Revolution Medicines must individually approve each request before the drug can be shipped.

"There's no shortage of demand for patients at all stages, at all times since their time of diagnosis, who are anxiously waiting to have it available," said Dr. Eddy Lou, an oncologist quoted by PBS [15]. The volume of inquiries has been substantial: one Targeted Oncology report noted that "easily half of patients are asking about this drug" [16].

But the physician-initiated request process creates a structural bottleneck. Oncologists at major academic medical centers — MD Anderson, Memorial Sloan Kettering, Dana-Farber — have dedicated research infrastructure, regulatory affairs staff, and established relationships with pharmaceutical companies. Community oncology practices, where the majority of U.S. cancer patients receive treatment, often do not [15][16].

The Molecular Testing Gap

To qualify for daraxonrasib, patients must have confirmed KRAS mutations — a determination that requires molecular testing, typically through next-generation sequencing (NGS). The Pancreatic Cancer Action Network recommends that all pancreatic cancer patients undergo biomarker testing to identify actionable mutations [6].

In practice, testing rates fall well short of universal. A 2025 physician survey published in BMC Cancer found that reimbursement challenges were the most-cited barrier to NGS implementation, reported by 87.5% of respondents. Seventy-two percent flagged prior authorization requirements as the primary reimbursement obstacle. Other barriers included lack of familiarity with NGS methodologies (81%) and lack of clinical utility evidence sufficient to satisfy payers (80%) [17].

The costs are nontrivial. If all 60,000-plus newly diagnosed pancreatic cancer patients annually underwent comprehensive NGS testing, the aggregate cost to the healthcare system would exceed $200 million per year [18]. For individual community oncology practices operating on thin margins, absorbing the upfront cost of testing — before reimbursement, if it comes at all — is a significant financial risk.

The disparities break along predictable lines. A study in the Journal of Clinical Oncology found that minorities, males, and individuals living in rural counties are disproportionately affected by pancreatic cancer, and that rural counties saw faster increases in incidence between 2009 and 2018 [19]. Research on KRAS biomarker testing in colorectal cancer — a reasonable proxy for molecular testing infrastructure — showed that patients in urban areas received testing more frequently than those in rural settings [20]. A systematic review documented significant sociodemographic disparities in access to equitable pancreatic oncology care across multiple dimensions, including race, income, and geography [21].

The result: patients most likely to need daraxonrasib are often treated at facilities least equipped to determine whether they qualify for it.

What the Trial Data Shows — and What It Doesn't

The RASolute 302 results are strong by the standards of pancreatic cancer research. A 60% reduction in the risk of death, a near-doubling of median survival, and statistically significant improvements in both progression-free survival and overall survival represent outcomes not previously seen in any Phase 3 trial for this disease [3].

But oncologists and biostatisticians have raised several caveats worth noting. The trial was open-label — neither patients nor outcome assessors were blinded to treatment assignment [5]. In oncology, where subjective endpoints like tumor response assessment can be influenced by knowledge of treatment, open-label designs introduce potential bias. While overall survival is considered a hard endpoint less susceptible to such bias, progression-free survival assessments may be affected.

The drug is also not a cure. "This is not a panacea," one researcher cautioned in an NBC News report. Tumors eventually develop resistance mechanisms and resume growth [22]. Median progression-free survival, while significantly improved, still measured in months, meaning most patients eventually progressed on daraxonrasib.

Additionally, the trial enrolled patients who had already failed at least one prior line of therapy. Whether daraxonrasib performs comparably in the first-line setting — where it would be given to newly diagnosed patients — is being tested in the upcoming RASolute 303 trial, a three-arm Phase 3 study comparing daraxonrasib alone, daraxonrasib plus gemcitabine/nab-paclitaxel, and chemotherapy alone [23].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Pricing Question

Daraxonrasib does not yet have a commercial price. During the expanded access period, Revolution Medicines is supplying the drug at no cost. But comparable KRAS-class inhibitors offer a preview of likely pricing: sotorasib (Lumakras) carries a wholesale cost of approximately $5,200 per month, while adagrasib (Krazati) has a wholesale acquisition cost of $19,750 per 30-day supply [24][25].

Per-patient-per-month treatment costs for pancreatic cancer already average $15,480, according to a 2023 analysis in Cancers [26]. Adding a targeted therapy priced in the range of existing KRAS inhibitors would push total monthly costs well beyond $20,000 for many patients — a figure that exceeds the median monthly income for most American households.

Insurance coverage, when the drug reaches the commercial market, will be a critical variable. Historically, insurers have used several mechanisms to deny or delay coverage for new oncology drugs: classifying them as "investigational" or "experimental," requiring prior authorization and step therapy, or imposing specialty tier copayments that shift thousands of dollars per month to patients [27]. A legal analysis by Debofsky & Associates noted that insurers routinely deny coverage for cancer treatments by claiming a "lack of medical necessity," even when the drug has an FDA indication [28].

The Pancreatic Cancer Action Network and organizations like the American Cancer Society offer resources to help patients appeal denials and access financial assistance programs [6][27]. But the administrative burden — filing appeals, gathering documentation, waiting for reviews — consumes time that patients with a median survival measured in months cannot spare.

The International Access Gap

The United States generally approves oncology drugs before other major markets. The FDA approved 95% of oncology therapies first compared to the European Medicines Agency, with a median delay of 241 days for European marketing authorization [29]. Germany offers the shortest health technology assessment timeline at approximately 210 days and achieves a 100% reimbursement rate for reviewed oncology medicines. The U.K.'s National Health Service operates a Cancer Drugs Fund that provides conditional access to therapies while full health technology assessments are completed [30].

Canada faces longer delays: a study in Current Oncology estimated that delayed access to oncology drugs cost measurable patient outcomes, with review timelines stretching 12–18 months in most countries after initial regulatory approval [31].

For daraxonrasib specifically, Revolution Medicines has said it intends to submit data to "global regulatory authorities," but no specific timeline has been provided for filings outside the United States [11]. Patients in Canada, Europe, and the U.K. face the prospect of waiting months to years after U.S. expanded access began before the drug becomes routinely available in their health systems.

Policy Levers and Political Realities

Several policy mechanisms could affect daraxonrasib access within the next two years.

Medicare drug price negotiation under the Inflation Reduction Act. CMS has already negotiated prices for 10 drugs effective in 2026, with 15 more selected for 2028 implementation. The second cycle includes several oncology drugs: acalabrutinib (Calquence), enzalutamide (Xtandi), palbociclib (Ibrance), and pomalidomide (Pomalyst) [32][33]. Daraxonrasib, as a newly launched drug, would not be eligible for negotiation for at least several years — the IRA's small-molecule drugs must be on the market for at least nine years before becoming eligible for selection. The pharmaceutical industry has challenged the negotiation program in court, arguing it amounts to price-setting rather than genuine negotiation [34].

Accelerated approval reform. The FDA has tightened oversight of its accelerated approval pathway, requiring sponsors to have confirmatory trials actively enrolling patients before approval is granted and shortening the timeline for withdrawal of approvals when confirmatory studies fail. The average time from accelerated to full approval for oncology drugs decreased from 4.3 years (1992–2013) to 2.3 years (2014–2024) [35]. If daraxonrasib receives accelerated approval based on the RASolute 302 data, the confirmatory study (RASolute 303) would need to be underway — which it is.

State-level price transparency laws. Multiple states have enacted or are considering laws requiring pharmaceutical manufacturers to disclose pricing information, justify price increases, and report development costs. These laws vary in scope and enforcement mechanisms, and the pharmaceutical industry has opposed them, arguing they create compliance burdens and may discourage investment in drug development.

Expanded access reform. The Right to Try Act (2018) created a pathway for patients with life-threatening conditions to access investigational drugs outside the FDA's expanded access framework, but uptake has been limited. The law does not require manufacturers to provide the drug, and most patients still rely on FDA-authorized expanded access programs — which, in daraxonrasib's case, are subject to Revolution Medicines' individual approval [12].

What Patients Face Now

The gap between clinical trial results and routine clinical availability is, for pancreatic cancer patients, not an abstraction. With a median survival of 6.7 months on standard chemotherapy, each month of delay in access represents a meaningful fraction of remaining life.

The Let's Win Pancreatic Cancer Foundation has published a detailed guide for patients seeking to access daraxonrasib, outlining the steps required: confirm KRAS mutation status through molecular testing, identify a treating oncologist willing to initiate an expanded access request, and contact Revolution Medicines' medical information team [23]. The Pancreatic Cancer Action Network similarly provides navigation resources [6].

But these guides underscore the reality that accessing the drug requires patients to be their own advocates — or to have advocates acting on their behalf — at a point when many are managing debilitating symptoms, undergoing active treatment, or dealing with the logistical and financial burdens that accompany a terminal cancer diagnosis.

An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026 [1]. Over 90% of them will have KRAS mutations that daraxonrasib was designed to target [7]. How many of them will actually receive the drug before formal FDA approval remains unknown. The clinical evidence suggests it could meaningfully extend their lives. The question is whether the systems meant to deliver it can keep pace with the disease.